Safety and adverse event profile of duloxetine

Expert Opinion on Drug Safety

Volumn 4, Issue 6, 2005, Pages 987-993

  Wernicke, Joachim F ^a   Gahimer, James ^a   Yalcin, Ilker ^a   Wulster Radcliffe, Meghan ^a   Viktrup, Lars ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Adverse event; Duloxetine; Safety

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; AMINOPHYLLINE; ANTACID AGENT; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DESIPRAMINE; DULOXETINE; FAMOTIDINE; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PLACEBO; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANORGASMIA; BODY WEIGHT DISORDER; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ALCOHOL INTERACTION; DRUG COMPETITION; DRUG CONJUGATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG OVERDOSE; DRUG PACKAGING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HEART DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERHIDROSIS; HYPERSOMNIA; HYPOGLYCEMIA; HYPOMANIA; INCREASED APPETITE; INSOMNIA; LIBIDO DISORDER; LIVER CELL DAMAGE; LIVER DYSFUNCTION; LIVER TOXICITY; MAJOR DEPRESSION; MANIA; MAXIMUM PERMISSIBLE DOSE; META ANALYSIS; METABOLIC DISORDER; MUSCLE WEAKNESS; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; NOSE CONGESTION; OBSTRUCTIVE JAUNDICE; ORGASM DISORDER; ORTHOSTATIC HYPOTENSION; PAIN; PARESTHESIA; QT PROLONGATION; REVIEW; SEXUAL DYSFUNCTION; SOMNOLENCE; STRESS INCONTINENCE; SUICIDAL BEHAVIOR; SUICIDE; SYSTEMATIC REVIEW; TACHYCARDIA; URINE RETENTION; VIRUS INFECTION; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSIVE DISORDER, MAJOR; DIABETIC NEUROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HALF-LIFE; HUMANS; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; URINARY INCONTINENCE, STRESS;

EID: 27944456892     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.6.987     Document Type: Review

References (38)

1. BERK M, DU PLESSIS AD, BIRKETT M, RICHARDT D: An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Int. Clin. Psychopharmacol. (1997) 12:137-140.
2. GOLDSTEIN DJ, MALLINCKRODT C, LU Y et al.: Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J. Clin. Psychiatry (2002) 63:225-231.
3. DETKE MJ, LU Y, GOLDSTEIN DJ et al.: Duloxetine, 60mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J. Clin. Psychiatry (2002) 63:308-315.
4. DETKE MJ, LU Y, GOLDSTEIN DJ et al.: Duloxetine 60mg once daily dosing versus placebo in the acute treatment of major depression. J. Pychiatr. Res. (2002) 36:383-390.
5. RASKIN J, GOLDSTEIN DJ, MALLINCKRODT C et al.: Duloxetine in the long-term treatment of major depressive disorder. J. Clin. Psychiatry (2003) 64:1237-1244.
6. NORTON PA, ZINNER NR, YALCIN I, BUMP RC: Duloxetine versus placebo in the treatment of stress urinary incontinence. Am. J. Obstet. Gynecol. (2002) 187:40-48.
7. DMOCHOWSKI RR, MIKLOS JR, NORTON PA, ZINNER NR, YALCIN I, BUMP RC: Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J. Urol. (2003) 170:1259-1263.
8. VAN KERREBROECK P, ABRAMS P, LANGE R et al.: Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. Br. J. Obstet. Gynaecol. (2004) 111:249-257.
9. MILLARD RJ, MOORE K, RENCKEN R, YALCIN I, BUMP RC: Duloxetine versus placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int. (2004) 93:311-318.
10. HUDSON JI, WOHLREICH MM, KAJDASZ DK, MALLINCKRODT CH, WATKIN JG, MARTYNOV OV: Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum. Psychopharmacol. (2005) 20:327-341.
11. HURLEY D, TURNER CL, YALCIN I, VIKTRUP L, BAYGANI SK: Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety. Eur. J. Obstet. Gynecol. Reprod. Biol. (2005) (In Press).
12. GOLDSTEIN DJ, LU Y, DETKE MJ, LEE TC, IYENGAR S: Duloxetine versus placebo in patients with painful diabetic neuropathy. Pain (2005) 116:109-118.
13. MONTGOMERY SA, KASPER S: Depression: a long-term illness and its treatment. Int. Clin. Psychopharmacol. (1998) 6:S23-S26.
14. REIMHERR FW, AMSTERDAM JD, QUITKIN FM et al.: Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am. J. Psychiatry (1998) 155:1247-1253.
15. HIRSCHFELD RM, MONTGOMERY SA, AGUGLIA E: Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J. Clin. Psychiatry (2002) 63:826-837.
16. DETKE MJ, WILTSE CG, MALLINCKRODT CH et al.: Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur. Neuropsychopharmacol. (2004) 14:457-470.
17. PIAZZA LA, MARKOWITZ JC, KOCSIS JH et al.: Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. Am. J. Psychiatry (1997) 154:1757-1759.
18. DELGADO PL, BRANNAN SK, MALLINCKRODT CH et al.: Sexual functioning in patients with major depressive disorder: duloxetine compared with paroxetine and placebo. J. Clin. Psychiatry (2005) 66:686-692.
19. PEET M: Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br. J. Psychiatry (1994) 164:549-550.
20. DUNNER DL, D'SOUZA DN, KAJDASZ DK, DETKE MJ, RUSSELL JM: Is treatment-associated hypomania rare with duloxetine: Secondary analysis of controlled trials in non-bipolar depression. J. Affect. Disord. (2005) 87:115-119.
21. VIKTRUP L, PERAHIA DG, TYLEE A: Duloxetine treatment of stress urinary incontinence in women does not induce mania or hypomania. Prim. Care Companion J. Clin. Psychiatry (2004) 6:239-243.
22. VIKTRUP L, YALCIN I: Duloxetine treatment of stress urinary incontinence in women: effects of demographics, obesity, chronic lung disease, hypoestrogenism, diabetes mellitus, and depression on efficacy. Br. J. Gen. Pract. (2005) submitted.
23. CYMBALTA PACKAGE INSERT. Indianapolis, IN: Eli Lilly and Company (2005).
24. ABRAMS P, CARDOZO L, FALL M et al.: The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. J. Obstet. Gynecol. (2002) 187:116-126.
25. VIKTRUP L, PANGALLO BA, DETKE MJ, ZINNER NR: Urinary side effects of duloxetine in the treatment of depression and stress urinary incontinence. Prim. Care Companion J. Clin. Psychiatry (2004) 6:65-73.
26. MURRAY JB: Cardiac disorders and antidepressant medications. J. Psychol. (2000) 134:162-168.
27. SZABADI E, GASZNER P, BRADSHAW CM: The peripheral anticholinergic activity of tricyclic antidepressants: comparison of amitriptyline and desipramine in human volunteers. Br. J. Psychiatry (1980) 137:433-439.
28. GLASSMAN AH, PREUD'HOMME XA: Review of the cardiovascular effects of heterocyclic antidepressants. J. Clin. Psychiatry (1993) 54(Suppl.): 16-22.
29. COMMITTEE ON SAFETY MEDICINES. QT interval prolongation with antipsychotics. Curr. Probl. Pharmacovig. (2001) 27:4.
30. GLASSMAN AH, BIGGER JT: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry (2001) 158:1774-1782.
31. SHARMA A, GOLDBERG MJ, CERIMELE BJ: Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J. Clin. Pharmacol. (2000) 40:161-167.
32. NEMEROFF CB, SCHATZBERG AF, GOLDSTEIN DJ et al.: Duloxetine for the treatment of major depressive disorder. Psychopharmacol. Bull. (2002) 36(4):106-132.
33. DERBY M, ZHANG L, GONZALES C, CHAPPELL J, LUCAS R, CALLAGHAN JT: Poster presented at the American Society for Clinical Pharmacology and Therapeutics, March 2-5, Orlando, Florida, USA (2005).
34. ZHANG L, DERBY M, GONZALES C et al.: Poster presented at the American Society for Clinical Pharmacology and Therapeutics, March 2-5, Orlando, Florida, USA (2005).
35. MOLLER HJ: Antidepressants - do they decrease or increase suicidality? Pharmacopsychiatry (1992) 25:249-253.
36. SKINNER MH, KUAN HY, PAN A et al.: Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin. Pharmacol. Ther. (2003) 73:170-177.
37. LANTZ RJ, GILLESPIE TA, RASH TJ et al.: Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab. Dispos. (2003) 31:1142-1150.
38. WOHLREICH MM, MALLINCKRODT CH, WATKIN JG, HAY DP: Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study. BMC Geriatr. (2004) 4:11.